Table 1.
Baseline clinicopathologic characteristics of patients with TFE3-tRCC.
| Clinicopathologic characteristics | Total (n = 68) |
| Age, median (range) | 32.5 (5–70) |
| Gender,n(%) | |
| Male | 26 (39.7%) |
| Female | 42 (60.3%) |
| Tumor size, median (cm, range) | 4.7 (1.4–19.6) |
| T stage,n(%) | |
| ≤T2 | 59 (86.8%) |
| ≥T3 | 9 (13.2%) |
| N stage,n(%) | |
| N0 | 52 (76.5%) |
| N1 | 16 (23.5%) |
| M stage,n(%) | |
| M0 | 61 (89.7%) |
| M1 | 7 (10.3%) |
| ISUP grade,n(%) | |
| ≤ 2 | 31 (45.6%) |
| ≥ 3 | 37 (54.4%) |
| Nephrectomy,n(%) | |
| Nephron-sparing surgery | 27 (39.7%) |
| Radical nephrectomy | 41 (60.3%) |
TFE3-tRCCTFE3-translocation renal cell carcinoma, ISUP The International Society of Urological Pathology.